Syngene International profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Returns
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
6.6%6.6%11.1%13.0%13.4%
4.6%4.6%7.7%8.5%8.2%
8.5%8.5%11.7%12.2%12.7%
5.1%8.6%11.8%12.7%13.5%
Margins
21.3%24.6%28.6%29.1%29.3%
12.5%12.5%16.7%16.9%17.8%
—−149.1%13.5%7.0%—
7.2%11.0%18.1%17.8%18.6%
5.3%8.5%13.6%14.6%14.5%
—8.5%13.6%—14.5%
14.6%14.6%10.9%15.2%9.6%
Additional
26.2%22.9%24.8%17.9%21.8%
—15.9%10.1%9.9%8.6%
6.6%5.6%9.9%11.7%12.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNGENE₹366.85

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹14,780 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity13.4312.9511.056.626.62
Return on Assets8.158.517.664.574.57
Return on Capital Employed12.6512.2011.718.548.54
Return on Invested Capital13.5512.7211.848.625.13
Margins
EBITDA Margin29.2629.0828.6024.5721.32
Operating Margin17.7916.8716.7312.4512.45
Incremental Operating Margin—6.9713.46-149.12—
Pretax Margin18.5917.8018.1210.997.16
Net Income Margin14.5414.6213.628.475.28
Net Income to Common Margin14.54—13.628.47—
FCF Margin9.5615.2310.9114.6314.63
Additional
Effective Tax Rate21.7717.8524.8122.9326.21
Dvd Payout Ratio8.639.8610.1415.91—
Sustainable Growth Rate12.2711.679.935.576.62
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.